(Q46425887)

22 December 2017

review article

1 reference

title

Insights from in vivo modification of adrenergic receptor gene expression (English)

1 reference

22 December 2017

2

Kobilka BK

1 reference

22 December 2017

author name string

Rohrer DK

series ordinal

1

1 reference

22 December 2017

publication date

1 January 1998

1 reference

22 December 2017

Annual Review of Pharmacology and Toxicology

published in

1 reference

22 December 2017

volume

38

1 reference

22 December 2017

page(s)

351-373

1 reference

22 December 2017

Antisense technology reveals the alpha2A adrenoceptor to be the subtype mediating the hypnotic response to the highly selective agonist, dexmedetomidine, in the locus coeruleus of the rat.

cites work

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Expression of alpha 1 adrenergic receptor subtype mRNAs in the rat cardiovascular system with aging

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Death before birth: clues from gene knockouts and mutations

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Genetic alteration of alpha 2C-adrenoceptor expression in mice: influence on locomotor, hypothermic, and neurochemical effects of dexmedetomidine, a subtype-nonselective alpha 2-adrenoceptor agonist.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

(+)-Niguldipine binds with very high affinity to Ca2+ channels and to a subtype of alpha 1-adrenoceptors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Intracoronary injections of salbutamol demonstrate the presence of functional beta 2-adrenoceptors in the human heart

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Rapid beta-adrenergic modulation of cardiac calcium channel currents by a fast G protein pathway

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Inotropic therapy for the failing myocardium

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

The family of G-protein-coupled receptors.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Dual trophic effects of the alpha 1-adrenergic receptor in cultured neonatal rat heart muscle cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Alteration in energetics in patients with left ventricular dysfunction after myocardial infarction: increased oxygen cost of contractility

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Germ line integration and Mendelian transmission of the exogenous Moloney leukemia virus

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Ecdysone-inducible gene expression in mammalian cells and transgenic mice.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplantation blastocysts injected with viral DNA

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Molecular cloning and expression of the cDNA for the hamster alpha 1-adrenergic receptor

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Efficacy of beta 1-adrenergic receptors is lower than that of beta 2-adrenergic receptors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Comparison of drugs with different selectivity for central alpha 1-and alpha 2-adrenoceptors in animal models of epilepsy.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Central hypotensive effects of the alpha2a-adrenergic receptor subtype.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Beta 2-adrenoceptor-mediated positive inotropic effect of adrenaline in human ventricular myocardium. Quantitative discrepancies with binding and adenylate cyclase stimulation

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Targeted gene replacement.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Alpha 2-adrenoceptors: more subtypes but fewer functional differences.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Vascular alpha-adrenoceptors: from the gene to the human

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Molecular characterization of the human beta 3-adrenergic receptor

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Uptake of radioligands by rat heart and lung in vivo: CGP 12177 does and CGP 26505 does not reflect binding to beta-adrenoceptors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Functional redundancy of the muscle-specific transcription factors Myf5 and myogenin

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Specific atrial overexpression of G protein coupled human beta 1 adrenoceptors in transgenic mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Structure and function of the beta 3-adrenergic receptor

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Differentiation of β-adrenoceptors in right atrium, diaphragm and adipose tissue of the rat, using stereoisomers of propranolol, alprenolol, nifenalol and practolol

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Agonist and antagonist characterization of a putative adrenoceptor with distinct pharmacological properties from the alpha- and beta-subtypes

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Delineation of the distribution of beta-adrenergic receptor subtypes in canine myocardium

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Transgenic mice carrying the human beta 2-adrenergic receptor gene with its own promoter overexpress beta 2-adrenergic receptors in liver.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Differentiation of Receptor Systems activated by Sympathomimetic Amines

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Infection of preimplantation mouse embryos and of newborn mice with leukemia virus: tissue distribution of viral DNA and RNA and leukemogenesis in the adult animal

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Functional beta3-adrenoceptor in the human heart

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Differentiation of receptors responsive to isoproterenol

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Cardiac alpha-adrenoceptors: postjunctional and prejunctional

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Introduction of a subtle mutation into the Hox-2.6 locus in embryonic stem cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

A point mutation of the alpha 2-adrenoceptor that blocks coupling to potassium but not calcium currents

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Specific alpha 1-adrenergic receptor subtypes modulate catecholamine-induced increases and decreases in ventricular automaticity

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Regions of the alpha 1-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Cloning of the cDNA for the human beta 1-adrenergic receptor

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Distribution of alpha 1C-adrenergic receptor mRNA in adult rat tissues by RNase protection assay and comparison with alpha 1B and alpha 1D.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Pharmacological subclassification of alpha 1-adrenoceptors in vascular smooth muscle

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Decreased blood pressure response in mice deficient of the alpha1b-adrenergic receptor

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Transgenic animals as new approaches in pharmacological studies

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Cardiac myocyte hypertrophy is associated with c-myc protooncogene expression

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Costimulation of adenylyl cyclase and phospholipase C by a mutant alpha 1B-adrenergic receptor transgene promotes malignant transformation of thyroid follicular cells.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Rescue of the En-1 mutant phenotype by replacement of En-1 with En-2

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Transgenesis in the rat and larger mammals

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Transgenic mice with cardiac overexpression of alpha1B-adrenergic receptors. In vivo alpha1-adrenergic receptor-mediated regulation of beta-adrenergic signaling

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Downregulation of myocardial beta-adrenergic receptors. Receptor subtype selectivity

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

On the presence and distribution of ?-adrenoceptors in the heart of various mammalian species

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Functional interactions of recombinant alpha 2 adrenergic receptor subtypes and G proteins in reconstituted phospholipid vesicles

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Substitution of a mutant alpha2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Demonstration of alpha 1A- and alpha 1B-adrenoceptor binding sites in human brain tissue

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Non-injection methods for the production of embryonic stem cell-embryo chimaeras

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Inducible gene targeting in mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Inducible site-directed recombination in mouse embryonic stem cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Targeted disruption of the beta 3-adrenergic receptor gene.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1146/ANNUREV.PHARMTOX.38.1.351

Identifiers

DOI

10.1146/ANNUREV.PHARMTOX.38.1.351

1 reference

22 December 2017

PubMed ID

9597159

1 reference

22 December 2017